SCHEMBL762714

SCHEMBL762714

CC1=NN(C)c2ccccc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 3/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
DRD3 P35462 3/20 0.38
KDM4E B2RXH2 3/20 0.38
CYP3A4 P08684 3/20 0.38
GAA P10253 2/20 0.38
CYP1A2 P05177 2/20 0.38
CHRM2 P08172 2/20 0.38
CHRM1 P11229 2/20 0.38
TSHR P16473 2/20 0.38
MAPT P10636 2/20 0.38
PTGS1 P23219 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NOTUM Q6P988 1/20 0.37
DRD2 P14416 2/20 0.36
DRD1 P21728 2/20 0.36
DRD4 P21917 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL761241 0.82 MEN1 (0.41) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL761827 0.72 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL975897 0.69 MAOA (0.52) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL29351597 0.69 MAOA (0.52) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL3957285 0.68 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
Iodide SCHEMBL11862710 0.67 MAOA (0.50) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL29735917 0.67 MAOA (0.50) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL5160711 0.67 MEN1 (0.50) ALDH1A1HPGDMEN1KMT2ADRD3
SCHEMBL2392480 0.65 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL15258184 0.64 GAA (0.40) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138182-B2 Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2012-03-20 US disclosed
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD (JP) 2010-04-08 US disclosed
US-7655804-B2 N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide; cysteine protease inhibitors; for the treatment of inflammatory, immune, ischemic, respiratory,circulatory, neuronal, blood, hepatic and metabolic diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT SERPINB1, CTSZ, ELANE ALDH1A1 481/4885SMN1; SMN2 1513/4885HPGD 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.